Christou Constantina N, Ehrsson Ylva Tiblom, Westerbergh Johan, Risérus Ulf, Laurell Göran
Department of Surgical Sciences, Uppsala University, 751 85 Uppsala, Sweden.
Uppsala Clinical Research Center, Uppsala University, 751 85 Uppsala, Sweden.
Cancers (Basel). 2022 Jul 29;14(15):3696. doi: 10.3390/cancers14153696.
Studies on fatty acids (FAs) in patients with head and neck cancer (HNC) are limited. We aimed to investigate the longitudinal changes of circulating FAs in patients with HNC and to examine potential correlations of FA changes with treatment. The secondary aims were to investigate correlations of FAs with cytokines and patient-related factors, and if any FAs correlated with disease recurrence or death. A total of 174 patients with HNC were included before treatment and followed-up at three time points after the start of the treatment through blood sampling and body weight measurements. Serum FA profiling was assessed by gas chromatography. The total follow-up time was 3 years. The levels of almost all FAs changed from baseline to 7 weeks. The change in FA 14:0 was associated with treatment and the change in 18:3n-6 was associated with the patients' pre-treatment BMI. FAs 14:0 and 18:0 were correlated with weight changes from baseline to 7 weeks. IL-6 was correlated with three FAs at 7 weeks and with two FAs at 1 year. Patients with higher levels 20:5n-3 at 3 months had a higher risk of all-cause death within 3 years (HR 2.75, 95% CI 1.22-6.21). Treatment, inflammation, and weight loss contributed in a complex manner to the altered FA profile in the studied cohort. The association between IL-6 and FAs in patients with HNC is in line with earlier studies and suggests the opportunity for regulating inflammation in HNC patients through modulation of FAs.
对头颈部癌(HNC)患者脂肪酸(FAs)的研究有限。我们旨在调查HNC患者循环脂肪酸的纵向变化,并研究脂肪酸变化与治疗之间的潜在相关性。次要目的是研究脂肪酸与细胞因子和患者相关因素的相关性,以及是否有任何脂肪酸与疾病复发或死亡相关。共有174例HNC患者在治疗前入组,并在治疗开始后的三个时间点通过采血和体重测量进行随访。通过气相色谱法评估血清脂肪酸谱。总随访时间为3年。几乎所有脂肪酸的水平从基线到7周都发生了变化。脂肪酸14:0的变化与治疗相关,18:3n-6的变化与患者治疗前的体重指数相关。脂肪酸14:0和18:0与从基线到7周的体重变化相关。白细胞介素-6在7周时与三种脂肪酸相关,在1年时与两种脂肪酸相关。在3个月时20:5n-3水平较高的患者在3年内全因死亡风险较高(风险比2.75,95%置信区间1.22-6.21)。治疗、炎症和体重减轻以复杂的方式导致了研究队列中脂肪酸谱的改变。HNC患者中白细胞介素-6与脂肪酸之间的关联与早期研究一致,提示通过调节脂肪酸来调节HNC患者炎症的可能性。